Connect with us

Health

Over 50% Of New Infections Now Outside Sub-Saharan Africa

Published

on

Over 50% Of New Infections Now Outside Sub-Saharan Africa

In a dramatic shift in the global HIV epidemic, a recent report by the Global HIV Prevention Coalition (GPC) reveals that over 50% of new HIV infections in 2023 occurred outside sub-Saharan Africa. The report estimates that approximately 1.3 million people contracted HIV last year, significantly surpassing the target of fewer than 370,000 new infections set for 2025. While sub-Saharan Africa has made notable progress in controlling the epidemic, the rising number of cases in other regions underscores a need for renewed focus on prevention efforts worldwide.

The GPC report highlights that the increase in infections is particularly severe in countries where key populations— such as men who have sex with men, sex workers, transgender individuals, and people who use drugs—are most affected. These groups, along with their sexual partners, now account for 55% of new HIV infections globally, up from 44% in 2010. This shift calls for targeted prevention strategies and increased investment in services for these vulnerable populations to effectively curb the spread of HIV.

Established in 2017, the GPC is a coalition of United Nations Member States, UNAIDS, donors, civil society, and private sector organizations, focusing on 40 countries to tackle the HIV prevention crisis. Prof. Sheila Tlou, GPC Co-chair and former Health Minister of Botswana, emphasized the need for resilient and equitable HIV prevention interventions. “The HIV epidemic has evolved; now more than ever, we need resilient capacity to deliver and manage integrated, differentiated, and equitable HIV prevention interventions,” Tlou stated, underscoring the importance of adaptable and inclusive approaches.

Progress has been notable in some areas, particularly in eastern and southern Africa. Countries such as Kenya, Malawi, and Zimbabwe have achieved over a 66% reduction in new infections, positioning them to meet the global target of a 90% reduction by 2030. This success is largely attributed to expanded access to effective HIV treatment and a sustained focus on primary prevention, illustrating the impact of continued investment and political commitment.

Despite these successes, significant gaps remain. Angeli Achrekar, UNAIDS Deputy Executive Director for Programmes, highlighted the urgency of the situation, pointing to new long-acting antiretroviral prevention methods like lenacapavir as promising advancements. However, accessibility and affordability of such technologies remain critical issues. Additionally, while pre-exposure prophylaxis (PrEP) is crucial in preventing new infections, with about 3.5 million people accessing it in 2023, this still falls short of the 10 million target for 2025.

Mitchell Warren, GPC cochair and Executive Director of AVAC, stressed the need for substantial policy changes to combat HIV effectively. “No matter how good the science or community leadership, HIV will not end unless we have significant policy changes to reverse criminalization and lessen the stigmatization of affected populations. It’s about people, and the people must lead,” Warren stated. The report highlights an urgent need for increased investments in HIV prevention, improved political leadership, and supportive legal and policy environments. With only US$2.4 billion available for primary prevention programs in 2023, far below the USD 9.5 billion needed by 2025, the challenge of addressing HIV will become increasingly complex and costly if current trends continue.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Trump Proposes Five-Way Split of Childhood Vaccines

Published

on

Trump Congratulates UK’s Farage, Ignores Starmer

Trump Proposes Five-Way Split of Childhood Vaccines

 

President Donald Trump has proposed splitting some childhood vaccines into five separate doses administered six months apart, a plan that vaccine experts say could leave children inadequately protected if the individual doses contain too little vaccine.

 

Trump made the proposal on Friday while speaking about his administration’s plans to alter the United States childhood immunisation schedule.

 

He said children could receive doses labelled one through five, with each containing what he described as about 20 per cent of the usual amount.

 

“Instead of a child going in and having a tremendous amount of different vaccines pumped into a big proportion of the body … we’re going to recommend that they do five doses marked one, two, three, four, five and that they be given in six-month intervals,” Trump said.

 

Trump did not identify all the vaccines that would be affected. He specifically referred to the polio vaccine, which he described as having been “amazing”.

 

However, vaccine specialist Dr Paul Offit, director of the Vaccine Education Centre at the Children’s Hospital of Philadelphia, said the proposed approach would not provide the intended protection.

 

Offit explained that vaccines are developed through dose-response studies to determine the smallest quantity capable of producing a protective immune response.

 

“You don’t want to give too much, where you know you don’t need all that, and you don’t want to give too little,” he said.

 

He told CNN that administering vaccines at doses below the level required to generate an immune response could make them ineffective rather than safer.

 

Trump also linked the proposed changes to autism, saying he expected them to lead to a “massive reduction” in autism.

 

However, decades of scientific research have found no causal link between childhood vaccines and autism.

 

The President’s comments came amid broader efforts by his administration to alter federal childhood vaccination policy.

 

In August, Trump signed an executive order seeking changes to the childhood immunisation schedule, including separating the measles, mumps and rubella vaccine into individual shots.

 

The administration has argued that the changes would reduce the number of vaccines given to children and address concerns about the existing schedule.

 

Health and Human Services Secretary Robert F. Kennedy Jr., who was with Trump as he outlined the proposal, has also backed changes to federal vaccine policy.

 

Kennedy spoke on Thursday at a conference organised by Children’s Health Defense, an organisation associated with vaccine scepticism.

Continue Reading

Health

DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus 

Published

on

WHO Releases New Guidelines for HIV Prevention

DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus 

 

The Democratic Republic of Congo has received 70,000 doses of the Ervebo Ebola vaccine from the global vaccine stockpile as health authorities intensify efforts to contain an outbreak of Bundibugyo virus disease.

 

The doses were released by the International Coordinating Group on Vaccine Provision following a request from the DRC government last week.

 

The development comes amid uncertainty over the effectiveness of Ervebo against the Bundibugyo strain, which is different from the Zaire ebolavirus for which the vaccine was originally developed and licensed.

 

Of the 70,000 doses, 20,000 have been allocated for a Phase 3 clinical trial designed to assess the vaccine’s potential impact against the Bundibugyo virus, while 50,000 doses will be administered to frontline and health workers in line with recommendations from the World Health Organisation’s Strategic Advisory Group of Experts on Immunization.

 

The effectiveness of Ervebo against Bundibugyo virus in humans is currently unknown.

 

However, preliminary laboratory and animal studies have suggested that the vaccine could offer some protection, prompting researchers to investigate its potential through the clinical trial.

 

The trial is expected to generate evidence that could guide future decisions on the use of Ervebo in outbreaks involving the Bundibugyo strain.

 

Health authorities have also stressed the importance of informed consent, saying people offered the vaccine must be adequately informed about its potential risks, benefits and limitations in relation to the current outbreak.

 

The ICG is made up of the WHO, International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières and UNICEF, while Gavi, the Vaccine Alliance, funds the global vaccine stockpile.

 

The WHO and Africa Centres for Disease Control and Prevention welcomed the allocation, supporting the DRC’s efforts to protect affected communities and contain the outbreak through a community-led response.

 

Both organisations said they would continue to support the DRC government in protecting communities, saving lives and generating scientific evidence that could strengthen Africa’s preparedness for future viral outbreaks.

 

The Bundibugyo outbreak has renewed attention on the need for effective vaccines and rapid scientific responses to emerging infectious diseases, with the outcome of the DRC trial expected to provide important information for future outbreak control.

 

Continue Reading

Health

Africa CDC, WHO demand urgent scale-up of DRC Ebola response

Published

on

WHO Releases New Guidelines for HIV Prevention

Africa CDC, WHO demand urgent scale-up of DRC Ebola response

 

The Africa Centres for Disease Control and Prevention and the World Health Organisation have called for an urgent scale-up of the community-led response to the Ebola outbreak in the Democratic Republic of the Congo.

 

The organisations said the response must focus on early detection, contact tracing, access to treatment, protection of frontline health workers and faster deployment of resources to affected communities.

 

The call followed a joint high-level mission to Uganda and the DRC on August 4 and 5, led by the WHO Director-General, Dr Tedros Adhanom Ghebreyesus; Director-General of Africa CDC, Dr Jean Kaseya; and WHO Regional Director for Africa, Dr Mohamed Janabi.

 

The delegation visited Kampala, Bunia and Kinshasa, where it held discussions with government officials, response coordinators, health workers, community representatives and development partners.

 

In Uganda, the delegation commended the country for successfully containing local transmission after it declared the end of its outbreak on July 28.

 

Uganda recorded 20 confirmed cases and two deaths, while all identified contacts completed their follow-up.

 

The organisations said Uganda’s experience demonstrated the importance of early detection, rapid contact tracing, coordinated government action, community engagement and effective cross-border surveillance.

 

However, they warned that continued transmission in the DRC meant neighbouring countries remained at risk and should maintain surveillance, laboratory readiness and cross-border coordination.

 

The delegation subsequently travelled to Bunia, the epicentre of the outbreak in Ituri Province, where it met provincial authorities, health workers, community leaders and response partners.

 

It also visited the Rwangole Ebola Treatment Centre to assess its readiness to expand access to timely and quality care.

 

The delegation stressed that communities would play a central role in containing the outbreak, urging authorities to ensure that residents receive accurate information from trusted sources and can report suspected cases and seek treatment without fear.

 

It also identified community, religious, women and youth leaders as critical partners in building confidence and ensuring that response measures reflect local realities.

Continue Reading

Trending